阿米卡星联合美罗培南成功治疗两例IMP-6产碳青霉烯酶肠杆菌菌血症
本文报道两例癌症术后IMP-6产碳青霉烯酶肠杆菌(CPE)菌血症患者,采用阿米卡星15 mg/kg(根据治疗药物监测调整给药间隔)联合美罗培南2000 mg每12小时输注3小时方案治疗2周,两例均治愈且未发生抗生素相关不良反应。
要点
- 阿米卡星联合大剂量延长输注美罗培南可能安全有效治疗IMP-6 CPE菌血症。
- 阿米卡星15 mg/kg给药间隔依据治疗药物监测调整,两药剂量均根据肌酐清除率确定。
- 美罗培南方案为2000 mg每12小时输注3小时,两例均完成2周疗程且无不良反应。
核心结论
- 阿米卡星联合大剂量延长输注美罗培南可能安全有效地治疗IMP-6 CPE所致菌血症。
研究设计与样本
- 病例报告,描述两例癌症术后发生IMP-6 CPE菌血症的患者。
主要发现
- 两例患者均经阿米卡星联合大剂量延长输注美罗培南治疗2周后菌血症治愈。
- 两例患者均未发生任何抗生素相关不良反应。
关键数值与推荐
- 阿米卡星15 mg/kg,给药间隔根据治疗药物监测调整。
- 美罗培南2000 mg每12小时输注3小时。
- 阿米卡星和美罗培南剂量均根据各患者肌酐清除率确定。
临床怎么用
- 对IMP-6 CPE菌血症,可考虑阿米卡星联合大剂量延长输注美罗培南方案。
- 阿米卡星给药间隔应基于治疗药物监测调整,两药剂量需根据肌酐清除率确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) are becoming increasingly common worldwide. Although CPE infections can be fatal, few reports in the literature have described effective and successful treatments for infectious diseases caused by several types of IMP CPE, and, to our knowledge, no reports have described the successful treatment of IMP-6 CPE infections. We describe two patients who developed bacteremia caused by IMP-6 CPE after surgery for cancer who were successfully treated with amikacin plus high-dose prolonged-infusion meropenem. Both patients were treated over a 2-week period using amikacin 15 mg/kg at various intervals based on therapeutic drug monitoring and meropenem 2000 mg infused over 3 hours every 12 hours. The dosages of amikacin and meropenem were determined based on the creatinine clearance of each patient. Both patients were cured of their bacteremia and did not experience any antibiotic-related adverse effects. Based on the outcomes of these patients, it appears that amikacin plus high-dose prolonged-infusion meropenem may be safe and effective for the treatment of bacteremia caused by IMP-6 CPE.
引用
- Nakakura I, Ogawa Y, Sakakura K, et al. IMP-6 Carbapenemase-Producing Enterobacteriaceae Bacteremia Successfully Treated with Amikacin-Meropenem in Two Patients. Pharmacotherapy. 2017. PMID: 28699652. doi:10.1002/phar.1984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。